BRPI0508814B8 - derivados de carbolina, bem como uso dos mesmos e composição farmacêutica - Google Patents

derivados de carbolina, bem como uso dos mesmos e composição farmacêutica

Info

Publication number
BRPI0508814B8
BRPI0508814B8 BRPI0508814A BRPI0508814A BRPI0508814B8 BR PI0508814 B8 BRPI0508814 B8 BR PI0508814B8 BR PI0508814 A BRPI0508814 A BR PI0508814A BR PI0508814 A BRPI0508814 A BR PI0508814A BR PI0508814 B8 BRPI0508814 B8 BR PI0508814B8
Authority
BR
Brazil
Prior art keywords
well
pharmaceutical composition
inhibiting
carboline derivatives
compounds
Prior art date
Application number
BRPI0508814A
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas Corson Donald
Qi Hongyan
Cao Liangxian
Tamilarasu Nadarajan
Hwang Seongwoo
Choi Soongyu
Joseph Lennox William
Moon Young-Choon
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of BRPI0508814A publication Critical patent/BRPI0508814A/pt
Publication of BRPI0508814B1 publication Critical patent/BRPI0508814B1/pt
Publication of BRPI0508814B8 publication Critical patent/BRPI0508814B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Pyrrole Compounds (AREA)
BRPI0508814A 2004-03-15 2005-03-15 derivados de carbolina, bem como uso dos mesmos e composição farmacêutica BRPI0508814B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55272504P 2004-03-15 2004-03-15
US60/552,725 2004-03-15
US11/079,420 US7601840B2 (en) 2004-03-15 2005-03-15 Carboline derivatives useful in the inhibition of angiogenesis
US11/079,420 2005-03-15
PCT/US2005/008481 WO2005089764A1 (en) 2004-03-15 2005-03-15 Carboline derivatives useful in the inhibition of angiogenesis

Publications (3)

Publication Number Publication Date
BRPI0508814A BRPI0508814A (pt) 2007-08-07
BRPI0508814B1 BRPI0508814B1 (pt) 2020-11-10
BRPI0508814B8 true BRPI0508814B8 (pt) 2021-05-25

Family

ID=34963165

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508814A BRPI0508814B8 (pt) 2004-03-15 2005-03-15 derivados de carbolina, bem como uso dos mesmos e composição farmacêutica

Country Status (22)

Country Link
US (2) US7601840B2 (enExample)
EP (2) EP2431369A3 (enExample)
JP (2) JP4857452B2 (enExample)
KR (2) KR101188778B1 (enExample)
CN (2) CN102408425A (enExample)
AU (1) AU2005222632B2 (enExample)
BR (1) BRPI0508814B8 (enExample)
CA (1) CA2559408C (enExample)
DK (1) DK1737461T3 (enExample)
EA (2) EA201200555A1 (enExample)
EC (1) ECSP066928A (enExample)
ES (1) ES2401335T3 (enExample)
IL (1) IL178079A (enExample)
MX (1) MXPA06010543A (enExample)
NO (1) NO338270B1 (enExample)
NZ (1) NZ588388A (enExample)
PL (1) PL1737461T3 (enExample)
PT (1) PT1737461E (enExample)
SG (2) SG151267A1 (enExample)
UA (1) UA92317C2 (enExample)
WO (1) WO2005089764A1 (enExample)
ZA (1) ZA200608176B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) * 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
EP1604011A4 (en) 2003-01-21 2009-12-09 Ptc Therapeutics Inc METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE THE EXPRESSION OF DEPENDENT GENES FROM A NON-TRANSLATED REGION, AND METHODS OF USING SAME
JP4671123B2 (ja) * 2003-06-23 2011-04-13 小野薬品工業株式会社 新規三環性複素環化合物
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
PL1737461T3 (pl) 2004-03-15 2013-05-31 Ptc Therapeutics Inc Pochodne karbolinowe użyteczne w hamowaniu angiogenezy
JP2008508356A (ja) * 2004-08-02 2008-03-21 スミスクライン ビーチャム コーポレーション Ｈｐｖ感染に有用な化合物
DK1829874T3 (da) 2004-12-22 2014-05-12 Ono Pharmaceutical Co Tricyklisk forbindelse og anvendelse deraf
WO2007002051A1 (en) * 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
ITMI20061581A1 (it) * 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
WO2008103470A2 (en) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
EP2214485B1 (en) * 2007-09-25 2016-07-20 Minerva Biotechnologies Corp. Methods for treatment of cancer
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
WO2010138659A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
SG176260A1 (en) * 2009-05-27 2012-01-30 Ptc Therapeutics Inc Processes for the preparation of substituted tetrahydro beta-carbolines
US8703726B2 (en) 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
WO2010138695A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
EP2434891B9 (en) 2009-05-27 2021-05-05 PTC Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
WO2011063223A1 (en) 2009-11-20 2011-05-26 Southern Research Institute TETRAHYDRO-β-CARBOLINE DERIVATIVES, SYNTHESIS AND USE THEREOF
CN102250127B (zh) * 2010-05-19 2013-06-19 首都医科大学 两个氨基酸修饰的四氢咔啉衍生物及其制备方法和应用
JP5649170B2 (ja) * 2010-11-26 2015-01-07 国立大学法人 千葉大学 テトラヒドロ−β−カルボリン誘導体及びその製造方法
CN102424681B (zh) * 2011-10-24 2014-10-15 华东师范大学 酰基四氢-β-咔啉类化合物及其衍生物、用途及其制备方法
US20130116219A1 (en) * 2011-11-04 2013-05-09 Alcon Research, Ltd. Antimicrobial carboline compounds
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
WO2015031759A1 (en) 2013-08-31 2015-03-05 The Wistar Institute Of Anatomy And Biology Methods and compositions for re-activating epstein-barr virus and screening compounds therefor
CN111978319B (zh) 2014-06-27 2023-08-11 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
PE20171330A1 (es) * 2014-12-18 2017-09-13 Hoffmann La Roche Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
US11931347B2 (en) * 2015-09-23 2024-03-19 Minerva Biotechnologies Corporation Method of screening for agents for differentiating stem cells
EP3355884B1 (en) 2015-10-01 2021-04-28 Olema Pharmaceuticals, Inc. TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
CN105330665B (zh) * 2015-11-04 2017-10-03 衡阳师范学院 一种抑制激肽释放酶klk7的化合物、制备方法和用途
DK3411034T3 (da) 2016-02-05 2021-01-11 Inventisbio Inc Selektiv østrogenreceptornedbrydere og anvendelser deraf
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
JP7018026B2 (ja) * 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN111372576A (zh) 2017-11-17 2020-07-03 塞尔利克斯生物私人有限公司 用于治疗眼部病症的组合物和方法
EP3810283B1 (en) 2018-06-21 2023-06-14 F. Hoffmann-La Roche AG Solid forms of the tartrate salt of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, process for their preparation and methods of their use in treating cancers
JP2021532193A (ja) 2018-08-03 2021-11-25 ピーティーシー セラピューティクス， インコーポレイテッド 生物学的に利用可能な経口剤形
WO2020055544A2 (en) 2018-08-17 2020-03-19 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
EP3860996A4 (en) * 2018-10-02 2022-08-31 Northwestern University BETA-CARBOLINES AS POSITIVE ALLOSTERIC MODULATORS OF HUMAN SEROTONIN RECEPTOR 2C (5-HT2C)
CN109400604B (zh) * 2018-10-25 2021-09-03 河北科技大学 2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚类化合物及用途
AU2020209767B2 (en) 2019-01-15 2025-03-06 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2021007146A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
CN110698474B (zh) * 2019-11-14 2021-11-02 福州大学 一种α位取代四氢-γ-咔啉类化合物及其制备方法和应用
CN113121527B (zh) * 2019-12-31 2024-09-06 上海辉启生物医药科技有限公司 三环类化合物及其用途
CN113546172A (zh) * 2020-04-24 2021-10-26 山东大学齐鲁医院 Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用
JP2024502270A (ja) 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
JP2025501285A (ja) 2021-12-31 2025-01-17 ピーティーシー セラピューティクス， インコーポレイテッド カルボリン化合物及びその使用
AU2023318665A1 (en) 2022-08-05 2025-01-23 Nextgen Bioscience Co., Ltd. Novel compound as hypoxia-inducible factor 1(hif-1) inhibitor or vascular endothelial growth factor (vegf) inhibitor, and pharmaceutical composition comprising same
CN116375702B (zh) * 2023-03-16 2025-06-17 贵州大学 一种含烷基或芳基的1，2，3，4-四氢-β-咔啉类化合物、组合物、制备方法和应用
CN116531371A (zh) * 2023-04-28 2023-08-04 中国人民解放军中部战区总医院 一类化合物在制备治疗与醛脱氢酶2活性相关的疾病或症状的药物中的用途

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055203A (en) * 1964-09-16 1967-01-18 Ici Ltd -ß-carboline derivatives, a process for their manufacture, and compositions containing them
US3492304A (en) * 1968-06-24 1970-01-27 Warner Lambert Pharmaceutical 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones
US4014890A (en) * 1976-03-23 1977-03-29 Pfizer Inc. Process for preparing indole derivatives
ATE165T1 (de) 1978-07-28 1981-09-15 Synthelabo Fluoren- und fluoranthenderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung.
FR2432025A1 (fr) 1978-07-28 1980-02-22 Synthelabo Derives d'imidazo et de pyrimido-pyrido-indoles, leur preparation et leur application en therapeutique
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5039801A (en) 1985-12-20 1991-08-13 The United States Of America As Represented By The Department Of Health & Human Services Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines
US4754038A (en) * 1987-02-26 1988-06-28 American Home Products Corporation Carboline histamine H1 antagonists
EP0300541B1 (en) 1987-07-20 1996-03-27 Duphar International Research B.V 8,9-anellated-1,2,3,4-tetrahydro-beta-carboline derivatives
EP0357122A3 (en) 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
US5166170A (en) 1989-07-03 1992-11-24 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
US5166204A (en) * 1989-11-01 1992-11-24 Toyama Chemical Co., Ltd. Isoindole derivatives and salts thereof and antitumor agent comprising the same
US5120543A (en) 1989-12-21 1992-06-09 The United States Of America As Represented By The Secretary Of Agriculture Molluscicidal β-carboline carboxylic acids and methods using the same
JPH03287586A (ja) 1990-04-02 1991-12-18 Taisho Pharmaceut Co Ltd テトラヒドロ―β―カルボリン誘導体
FR2662940B1 (fr) 1990-06-08 1994-10-14 Roussel Uclaf Utilisation de derives de la tetrahydro isoquinoleine pour la preparation de medicaments anti-tumoraux, application a titre de medicaments de derives de la tetrahydro isoquinoleine et produits derives de cette structure.
US5162336A (en) 1990-06-21 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Tetrahydro-pyrido-indoles as cholecystokinin and gastrin antagonists
US5187180A (en) 1990-07-26 1993-02-16 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
JPH04275221A (ja) 1991-03-01 1992-09-30 Taisho Pharmaceut Co Ltd 制癌効果増強剤
US5382569A (en) 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
JP3287586B2 (ja) 1991-07-09 2002-06-04 キヤノン株式会社 カラー画像処理方法、及びカラー画像処理装置
US5206377A (en) * 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
US5622960A (en) 1992-04-14 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Topoisomerase II inhibitors and therapeutic uses therefor
US5314898A (en) 1992-06-29 1994-05-24 Merck & Co., Inc. Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis
US5314900A (en) 1992-11-19 1994-05-24 Merck Frosst Canada, Inc. Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene biosynthesis
US6824976B1 (en) * 1993-04-02 2004-11-30 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
US5500431A (en) * 1993-04-14 1996-03-19 Eli Lilly And Company Tetrahydro-β-carbolines
EP0620222A3 (en) 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US5451600A (en) * 1994-04-19 1995-09-19 Hoffmann-La Roche Inc. Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors
FR2724384B1 (fr) 1994-09-14 1999-04-16 Cemaf Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament
ES2149945T3 (es) 1994-12-12 2000-11-16 Ciba Sc Holding Ag Colorantes azoicos, procedimiento de obtencion y utilizacion de los mismos.
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
US6376529B1 (en) 1995-06-07 2002-04-23 Peng Cho Tang Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
JP2000508302A (ja) * 1996-04-04 2000-07-04 エフ．ホフマン―ラ ロッシュ エイジー 抗転移剤としてのテトラヒドロ―β―カルボリン誘導体の使用
FR2748026B1 (fr) 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SK154498A3 (en) 1996-05-10 2000-01-18 Icos Corp Carboline derivatives, process for the preparation thereof, pharmaceutical compositions containing same and use of mentioned derivatives as drugs
US6013633A (en) 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US5892041A (en) * 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
WO1998037189A1 (en) * 1997-02-25 1998-08-27 Qbi Enterprises Ltd. Ires sequences with high translational efficiency and expression vectors containing the sequence
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6514981B1 (en) * 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
JP4275221B2 (ja) 1998-07-06 2009-06-10 リンテック株式会社 粘接着剤組成物および粘接着シート
GB9828709D0 (en) 1998-12-24 1999-02-17 Novartis Ag Assay
CN1370176A (zh) 1999-06-15 2002-09-18 布里斯托尔-迈尔斯斯奎布药品公司 取代的杂环稠合γ－咔啉
FR2796644B1 (fr) 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9918962D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
US6696418B1 (en) * 1999-09-01 2004-02-24 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US20020016298A1 (en) 1999-09-01 2002-02-07 Hay Bruce A. Somatostatin antagonists and agonists that act at the sst subtype 2 receptor
US6469047B1 (en) 1999-09-24 2002-10-22 Genentech, Inc. Tyrosine derivatives
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US20030158168A1 (en) 2000-08-09 2003-08-21 Giorgio Massimini Composition for combined use of aromatase inhibitors
US6720330B2 (en) 2000-11-17 2004-04-13 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
ES2241902T3 (es) * 2000-12-08 2005-11-01 Smithkline Beecham Corporation Compuestos antibacterianos.
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
BR0116429A (pt) 2000-12-20 2006-05-09 Bristol Myers Squibb Co piridoindóis substituìdos como agonistas e antagonistas da serotonina
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
ATE346067T1 (de) * 2001-02-12 2006-12-15 Lilly Icos Llc Carbolinderivate
ATE302775T1 (de) * 2001-02-12 2005-09-15 Lilly Icos Llc Carbolinderivate
WO2002077609A2 (en) * 2001-03-26 2002-10-03 Message Pharmaceuticals, Inc. Identification of compounds for the treatment or prevention of proliferative diseases
US6720331B2 (en) * 2001-04-03 2004-04-13 National Sun Yat-Sen University 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents
JP4216606B2 (ja) 2001-04-25 2009-01-28 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物
US6701957B2 (en) * 2001-08-16 2004-03-09 Fisher Controls International Llc Fluid pressure reduction device
DE60236605D1 (de) * 2001-09-05 2010-07-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
EP1438310B1 (en) 2001-10-19 2006-12-20 TransTech Pharma Inc. Beta-carbolin derivatives as ptp-inhibitors
US20030130171A1 (en) 2001-10-30 2003-07-10 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant microbial cells
PL373156A1 (en) 2001-12-14 2005-08-22 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
JP4328058B2 (ja) * 2002-04-12 2009-09-09 株式会社エイ・エル・エイ 糖尿病合併症を予防する組成物
JP2005529590A (ja) 2002-04-17 2005-10-06 ノバルティス アクチエンゲゼルシャフト ＡＲＥ含有ｍＲＮＡとＨｕＲタンパク質の結合のインヒビターの同定方法
US20030220377A1 (en) 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
WO2003103656A1 (ja) 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 Ｏ−置換ヒドロキシアリール誘導体
WO2004035047A1 (en) 2002-10-18 2004-04-29 F. Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
US8426194B2 (en) * 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
WO2004069831A1 (en) 2003-02-10 2004-08-19 Glenmark Pharmaceuticals Ltd. Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation
AU2003902023A0 (en) 2003-04-29 2003-05-15 The Australian National University A method of indole synthesis
GB0311201D0 (en) 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
KR20060017545A (ko) 2003-06-10 2006-02-23 스미스클라인 비참 코포레이션 테트라하이드로카르바졸 유도체 및 이들의 약제학적 용도
KR20060017544A (ko) 2003-06-12 2006-02-23 스미스클라인 비참 코포레이션 테트라히드로카르바졸 유도체 및 이의 약제학적 용도
US20060235012A1 (en) 2003-06-16 2006-10-19 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
EA200600069A1 (ru) 2003-06-20 2006-08-25 Коли Фармасьютикал Гмбх Низкомолекулярные антагонисты toll-подобных рецепторов (tlr)
JP4671123B2 (ja) 2003-06-23 2011-04-13 小野薬品工業株式会社 新規三環性複素環化合物
TW200509930A (en) 2003-06-25 2005-03-16 Elan Pharm Inc Methods and compositions for treating rheumatoid arthritis
US20050143371A1 (en) 2003-07-23 2005-06-30 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
JP2007509057A (ja) 2003-10-15 2007-04-12 カイロン コーポレイション ウイルス阻害のための組成物および方法
MXPA06008211A (es) 2004-01-23 2006-08-31 Chiron Corp Compuestos de tetrahidrocarbolina como agentes anticancer.
US20080103213A1 (en) 2004-03-05 2008-05-01 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of neurofibromatosis
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
PL1737461T3 (pl) 2004-03-15 2013-05-31 Ptc Therapeutics Inc Pochodne karbolinowe użyteczne w hamowaniu angiogenezy
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
AU2005231467A1 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
WO2005113003A2 (en) 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
JP2008508356A (ja) 2004-08-02 2008-03-21 スミスクライン ビーチャム コーポレーション Ｈｐｖ感染に有用な化合物
US8946444B2 (en) 2004-11-23 2015-02-03 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
US7696227B2 (en) 2007-04-13 2010-04-13 Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases

Also Published As

Publication number Publication date
ECSP066928A (es) 2007-02-28
MXPA06010543A (es) 2007-03-26
NO338270B1 (no) 2016-08-08
EA201200555A1 (ru) 2013-01-30
JP2007529534A (ja) 2007-10-25
SG151267A1 (en) 2009-04-30
HK1104961A1 (en) 2008-02-01
US7601840B2 (en) 2009-10-13
EP1737461B1 (en) 2012-12-12
NO20064519L (no) 2006-12-15
US20100125065A1 (en) 2010-05-20
WO2005089764A9 (en) 2007-09-13
CN1980672A (zh) 2007-06-13
AU2005222632B2 (en) 2012-02-09
IL178079A (en) 2015-04-30
CN1980672B (zh) 2011-05-04
PT1737461E (pt) 2013-03-18
EP1737461A1 (en) 2007-01-03
UA92317C2 (ru) 2010-10-25
US8367694B2 (en) 2013-02-05
KR101188778B1 (ko) 2012-10-10
KR20070026456A (ko) 2007-03-08
EA200601697A1 (ru) 2007-02-27
CA2559408A1 (en) 2005-09-29
CA2559408C (en) 2014-05-13
ZA200608176B (en) 2008-05-28
NZ588388A (en) 2012-05-25
CN102408425A (zh) 2012-04-11
JP2012012398A (ja) 2012-01-19
EP2431369A2 (en) 2012-03-21
SG184755A1 (en) 2012-10-30
JP4857452B2 (ja) 2012-01-18
US20070281962A2 (en) 2007-12-06
WO2005089764A1 (en) 2005-09-29
US20090227618A2 (en) 2009-09-10
ES2401335T3 (es) 2013-04-18
KR20120073287A (ko) 2012-07-04
BRPI0508814B1 (pt) 2020-11-10
PL1737461T3 (pl) 2013-05-31
IL178079A0 (en) 2006-12-31
DK1737461T3 (da) 2013-03-18
EA016575B1 (ru) 2012-06-29
AU2005222632A1 (en) 2005-09-29
BRPI0508814A (pt) 2007-08-07
EP2431369A3 (en) 2012-07-11
US20050272759A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
BRPI0508814B8 (pt) derivados de carbolina, bem como uso dos mesmos e composição farmacêutica
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
BRPI0915084B8 (pt) composto, e, composição farmacêutica
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
ECSP088835A (es) Terapia combinatoria que involucra antagonistas de alfa5beta1
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
DE602006014579D1 (de) Heteroalkylgebundene pyrimidinderivate
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
CL2007001648A1 (es) Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina.
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
BRPI0618577A8 (pt) Usos de rituximab
BRPI0507198A (pt) derivados de bisariluréia
UY30304A1 (es) Moduladores de mglur5 i
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CL2008001323A1 (es) Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESE

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.